Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead 3Q

Product sales were up 13% to $1.9 billion in the quarter. Antiviral product sales were $1.7 billion (+12%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead 3Q

3Q Revenues: $1.9 billion (+8%)

3Q Earnings: $702.2 million (+5%)

YTD Revenues: $6.0 billion (+20%)

YTD Earnings: $2.3 billion (+24%)

Comments: Product sales were up 13% to $1.9 billion in the quarter. Antiviral product sales were $1.7 billion (+12%), with Atripla sales up 23% to $742.7 million, Truvada sales up 8% to $668.7 million, and Viread sales up 9% to $184.3 million. Sales of Letairis for the treatment of pulmonary arterial hypertension were up 26% to $60.4 million. Sales of Ranexa for chronic angina increased 23% to $60.3 million. Royalty, contract and other revenues, primarily from collaborations, were $72.1 million, down from $152.4 million in 3Q09. This drop was primarily due to lower Tamiflu royalties from Roche, which were $34.5 million in the quarter, compared to $113.5 million in 3Q09.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters